Archived: 3rd Winter Conference
on Medicinal & Bioorganic Chemistry

January 24th - 29th 1999

Steamboat Springs Resort, Colorado

Book Now

Agenda

Sunday, January 24th 1999

Optimization in Chemical Synthesis

Program Chair: Victor Snieckus, Queen’s University

Victor Snieckus Queen’s University

Introduction

Carsten Bolm Institute Organische Chem., RhenischeWestfalische Technische Hochshule

Metal-Catalysed Asymmetric Oxidations

Gilbert Stork Columbia University

From Cincholoipin and Cantharidin to the Present

Monday, January 25th 1999

Optimization in Chemical Synthesis (cont.)

Program Chair: Victor Snieckus, Queen’s University

Pat Confabne DuPont Pharmaceuticals

Recent Advances in the Process R&D of Novel AIDS Therapeutics

Matthias Beller Technische Universitaet Munchen

Catalysis as a Key Technology for Environmentally Benign Synthesis of Pharmaceutically Important Amines and Amino

Paul Wender Stanford University

The Chemistry-Medicine Continuum: the Design of New Reactions in Connection with the Design of New Therapeutic Agents

Michael Martinelli Eli Lilly

The Total Synthesis of Cryptophycins, Potent Marine Natural Product Oncolytics

Lutz Tietze George-August Universitaet

Domino Reactions in Organic Synthesis, A Contribution to Efficiency, Economy, and Ecology in Chemistry

Methodologies for Parallel Array Medicinal Chemistry

Program Chair: Dan Flynn / Gunda Georg

Dan Flynn Amgen

Strategies for Parallel Synthesis: an Overview

Dennis Curran University of Pittsburgh

Parallel Synthesis with Fluorous Phase Reagents and Reactants

David Bergbrelter Texas A&M University

Soluble Polymers in Parallel Array Synthesis

Tuesday, January 26th 1999

Methodologies for Parallel Array Medicinal Chemistry (cont.)

Program Chair: Dan Flynn / Gunda Georg

Aubrey Mendonca IRORI

Building Blocks on Resins

Miles Siegel Eli Lilly

Sequestration Methods for Purification in Array Synthesis. Application to Specific Drug Discovery Projects

Daniel Pilipauskas Monsanto

Experimental Design Tools for Parallel Array Synthesis: Can We Shorten the Time from Synthesis Design to Validated Chemistry?

Applications of Structural Biology to Drug Discovery

Program Chair: Christie G. Broulliette, University of Alabama-Birmingham

Kenneth P. Murphy University of Iowa

Predicting Binding Energetics from Structure: Looking Beyond ∆G

Carol B. Post Purdue University

Structure and Energetics of Phosphotyrosine Protein-Peptide Complexes

Dagmar Ringe Brandeis University

Analysis of the Binding Surfaces of Proteins

Joseph Loo Parke-Daivs Pharmaceutical Research

Applications of Mass Spectrometry for Target Identification and Characterization

Gabriel Waksman Washington University School of Medicine

SH2 domains: from Structure to Energetics, a Dual Approach to the Study of Structure/Function Relationships

Wednesday, January 27th 1999

KEYNOTE | “Academic Organic Synthesis…Where do we go from here?”

Program Chair: Prof. Stephen Hannesian, Universite de Montreal

General Paper | WCMBC Student/Postdoctoral Fellowship Presentations

Program Chair: Peter Andrews, University of Queensland

Frederic Zecri Imperial College

Impurity Annihilation: A Strategy for Solution Phase Combinatorial Chemistry with Minimal Purification

 

Hui Liu Dartmouth College

An Iterative Synthesis of Semicorrins, Tripyrrolines and Related Materials

Hans Brauner-Osborne Royal Danish College of Pharmacy

Constitutive Activation o’ G-Protein Coupled Receptors

Simon Baker Imperial College

The Quest for Novel Antibiotics: Alkene Metathesis in the Construction of B-Lactams

Cynthia Shafer Purdue University

Trfluoromethylacivicin as a Mechnaistic Probe for IGP Synthase

Vidhya Iyer University of Minnesota

Inhibition of Breast Cancer Cell and Tumor Growth by Derivatives of AZT and AZU

Joshua Tullis University of Notre Dame

Synthesis Applications of Aymmetric Horner-Wadsworth-Emmons Condensations: Approaches to Marine Natural Products

David Reltz Monsanto

Novel Benzothiepine Ileal Bile Acid Transporter (IBAT) Inhibitors for the Treatment of Hypercholesterolemia

General Oral Papers | Poster Session

Program Chair: Michael Rafferty

Dennis Dean Merck & Co.

New Applications of High Specific Activity [36S]Sulfonamides for Photoalfinity Labelling

Andrea Leone-Bay Emisphare Technologies

Oral Delivery of Low Molecular Weight Heparin in Rats and Primates

Michael G. N. Russell Merck - Sharp & Dohme Research Laboratories

3-[3-Piperidin-1-yl)propyl]indoles as Highly Selective h5-HT 1D Agonists

Monte Rhodes Advanced Chemtech

Automated Solid Phase Organic Synthesis: Synthesis of Organic Molecules Through the Use of Air-Sensitive Reagents

Stanislav Gobec University of Ljubljana

Synthesis and Biochemical Evaluation of Phthalimido Derivatives as Potential Inhibitors of the D-Glutamic Acid-Adding Enzyme

Jean-Maire Ferland Boehringer-Ingelheim

Ligands for the Tyrosine Kinase p56kk SH2 Domain: Discovery of Potent Dipetides with Monocharged, Non-hydrolyzable Phoshate Replacements

Thomas Malone Parke-Davis Pharmaceutical Research Division

Design and Synthesis of a x-Conotoxin MVIIa Peptidomimetic

Eric Keeler Rapigene Inc.

The Synthesis of Cleavable Mass Spectrometry Tags: A System for SNP Genotyping

Thursday, January 28th 1999

Impact of Genomics Technologies on Pharmaceutical Research

Program Chair: Gary McMaster, Parke-Davis Pharmaceutical Research

Gary McMaster Parke-Davis Pharmaceuticals

Introduction

Timothy Harris AxyS Pharmaceuticals

Genetics, Genomics and Drug Discovery

David West Parke-Davis Laboratory of Molecular Genetics

Mouse Genetics/Genomics: Approaches for Identification of New Therapeutic Targets

David Bentley Sanger Centre

Overview of the Human Genome Project

Thomas Freeman Sanger Centre

High Throughput Screening of Gene Expression: It’s Emerging Role in Drug Discovery

Brent Kreider Phylos: PROfusions(tm)

Genetically tagged-Proteins for Functional Proteomics and Beyond

Carl Johnson NemaPharm

Using Model Animals to Identify Targets and Leads for Human Therapeutics

Multi-Drug Resistance

Program Chair: Lester Mitscher, University of Kansas

Lester Mitscher University of Kansas

Nature and Dimensions of the Problem

Daniel T. W. Chu Kosan Laboratories

Recent Progress in Novel Macrolides, Quinolones and Pyridones Directed at Overcoming Resistance

Kenneth Rinehart University of Illinois

Antitumor Compounds from Tunicates

Friday, January 29th 1999

Multi-Drug Resistance (cont.)

Program Chair: Les Mitscher, University of Kansas

Ving Lee Microcide Pharmaceuticals

Antimicrobial Resistance v.s. Small Molecules (i.e. The Chemical Evolution)

 

Leonard Katz Abbott Laboratories

Novel Erythromycin Analogs by Genetic Engineering

Bryan Norman Eli Lilly

Multiple Drug Resistance Inhibitors as Adjuncts in Anticancer Chemotherapy

Prabhavathi Fermandes Small Molecule Therapeuctics Inc.

Microbal Resistance: Novel Screens for a Contemporary Problem

Dinesh Patel Versicor

Combinatorial Chemistry Aided Anti-bacterial Drug Discovery

Kuo-Huing Lee University of North Caroline-Chapel Hill

Novel Antitumor Agents from Higher Plants

Media Sponsors